Literature DB >> 10486273

Dominant and shared T cell receptor beta chain variable regions of T cells inducing synovial hyperplasia in rheumatoid arthritis.

T Mima1, S Ohshima, M Sasai, K Nishioka, M Shimizu, N Murata, R Yasunami, H Matsuno, M Suemura, T Kishimoto, Y Saeki.   

Abstract

Previously, we demonstrated the presence of at least two distinct subpopulations of patients with rheumatoid arthritis (RA) employing a cell-transfer experiment using severe combined immunodeficient (SCID) mice. One group of patients, whose T cells derived from the rheumatoid joints, induced synovial hyperplasia (SH) in the SCID mice (the positive group). The other group did not display the induction of SH (the negative group). TCR/Vbeta gene usage analysis indicated that some dominant T cell subpopulations were oligoclonally expanding only in the rheumatoid joints, and not in the periphery of the patients of the positive group. Moreover, these T cell subpopulations were not seen in the joints of patients in the negative group or in non-RA patients. In addition, the preferential uses of certain TCR/Vbetas (Vbeta8, Vbeta12, Vbeta13, and Vbeta14) genes were demonstrated in these T cells. In this study, to investigate whether these T cells are driven by a certain antigen(s), the third complementarity determining regions (CDR3s) of TCR/Vbeta, especially Vbeta8 and Vbeta14 PCR products, were cloned and sequenced. As a result, a dominant CDR3 sequence, CASS-PRERAT-YEQ, was found in Vbeta14+ T cells from the rheumatoid joint of a patient (Patient 1) of the positive group with a Vbeta14 skew. The identical CDR3 sequence also predominated in Vbeta14+ T cells from the rheumatoid joint of another patient (Patient 7) of the positive group with a Vbeta14 skew. In addition, in the patients (Patients 4, 7, 8) of the positive group with a Vbeta8 skew, other dominant CDR3 sequences, CASS-ENS-YEQ and CASS-LTEP-DTQ, were found as in the case of Vbeta14. However, no identical CDR3 sequences were detected dominantly in the joints of the patients in the negative group or in non-RA patients. A Vbeta14+ T cell clone (TCL), named G3, with the identical CDR3 sequence, CASS-PRERAT-YEQ, was isolated successfully from Patient 1, and cell transfer of G3 with autologous irradiated peripheral mononuclear cells induced SH in the SCID mice. Taken together, these results suggest that T cells inducing SH, thought to be pathogenic for RA, might be driven by a certain shared antigen(s). Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486273     DOI: 10.1006/bbrc.1999.1128

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

Review 1.  Immune pathophysiology of aplastic anemia.

Authors:  Jaroslaw P Maciejewski; Antonio Risitano; Hoon Kook; Weihua Zeng; Guibin Chen; Neal S Young
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Inflammation, immune reactivity, and angiogenesis in a severe combined immunodeficiency model of rheumatoid arthritis.

Authors:  Laurie S Davis; Marian Sackler; Ruth I Brezinschek; Ellis Lightfoot; Jennifer L Bailey; Nancy Oppenheimer-Marks; Peter E Lipsky
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

3.  Limited heterogeneity of T cell receptor BV usage in aplastic anemia.

Authors:  W Zeng; J P Maciejewski; G Chen; N S Young
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

4.  Production and characterization of monoclonal IgM autoantibodies specific for the T-cell receptor.

Authors:  I F Robey; S F Schluter; D E Yocum; J J Marchalonis
Journal:  J Protein Chem       Date:  2000-01

5.  Collagen-specific T-cell repertoire in blood and synovial fluid varies with disease activity in early rheumatoid arthritis.

Authors:  Francesco Ria; Romina Penitente; Maria De Santis; Chiara Nicolò; Gabriele Di Sante; Massimiliano Orsini; Dario Arzani; Andrea Fattorossi; Alessandra Battaglia; Gian Franco Ferraccioli
Journal:  Arthritis Res Ther       Date:  2008-11-17       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.